

Ref: GLL/BSE/2022/Aug - 05

Date: August 12, 2022

To
Corporate Relations Manager
BSE Limited
Phiroje Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

To
Listing Manager
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex,
Opposite Sahajanand College,
120 Feet Ring Rd, Panjara Pol, Ambawadi,
Ahmedabad - 380 015

To
The Secretary
The Calcutta Stock Exchange Limited
#7, Lyons Range, Murgighata,
Dalhousie, Kolkata - 700 001

Sub: Outcome of the Board Meeting held on August 12, 2022 of Gennex Laboratories Limited

Ref: Regulation 29, 33 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

In just concluded Meeting of the Board Directors of the Company, the board has considered and approved:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2022 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2022 (annexed herewith).


This intimation is also uploaded in the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

For Gennex Laboratories Limited



Rajesh Vankadara
Company Secretary &
Compliance Officer
Membership #A44949

Gennex Laboratories Limited



GENNEX LABORATORIES LIMITED

CIN : L24230TG1990PLC011168

Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,
Dist : Sangareddy, Telangana - 502 325. INDIA

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2022

(Rs. In Lacs)

S No.	PARTICULARS	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income								
	Revenue from Operations	1,393.73	2,017.80	1,037.29	6,121.38	1,393.73	2,017.80	1,037.29	6,121.38
	Other Income	57.36	104.32	2.57	138.14	57.36	104.32	2.57	138.14
	Total Income	1,451.09	2,122.12	1,039.86	6,259.52	1,451.09	2,122.12	1,039.86	6,259.52
2	Expenses								
(a)	Cost of material consumed	1,240.42	1,348.91	650.36	4,001.04	1,240.42	1,348.91	650.36	4,001.04
(b)	Purchase of stock-in-trade	-	-	-	-	-	-	-	-
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	-423.22	-65.47	-123.18	-190.72	-423.22	-65.47	-123.18	-190.72
(d)	Employees Cost	185.86	206.64	166.18	696.86	185.86	206.64	166.18	696.86
(e)	Depreciation	17.89	34.24	20.19	78.85	17.89	34.24	20.19	78.85
(f)	Finance Cost	26.40	19.59	15.27	87.74	26.40	19.59	15.27	87.74
(g)	Other Expenses	303.09	449.76	180.82	1,076.40	303.09	449.76	180.82	1,076.40
	Total Expenses	1,350.44	1,993.67	909.63	5,750.17	1,350.44	1,993.67	909.63	5,750.17
3	Total Profit before exceptional Items & Tax.	100.65	128.45	130.23	509.35	100.65	128.45	130.23	509.35
4	Exceptional items	-	-	-	-	-	-	-	-
5	Total profit before tax	100.65	128.45	130.23	509.35	100.65	128.45	130.23	509.35
6	Tax expense for earlier years	-	-	-	-	-	-	-	-
	Curent tax	-25.33	-36.12	-34.80	-132.00	-25.33	-36.12	-34.80	-132.00
	Deferred Tax	-	14.97	-	14.97	-	14.97	-	14.97
	Total Tax Expenses	-25.33	-21.15	-34.80	-117.03	-25.33	-21.15	-34.80	-117.03
7	Net profit /(Loss)	75.32	107.30	95.43	392.32	75.32	107.30	95.43	392.32
8	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-	-	-
9	Total Profit (losss) for period	75.32	107.30	95.43	392.32	75.32	107.30	95.43	392.32
10	Other comprehensive income net of taxes		18.22		18.22		18.22		18.22
11	Total Comprehensive income for the period Total profit or loss, attributable to Profit or loss, attributable to owners of parent		125.52		410.54		125.52		410.54
12	Total Comprehensive income for the period attributable to Comprehensive income for the period attributable to owners of parent								
13	Total comprehensive income for the period attributable to owners of parent non controlling interests								
14	Details of equity share capital								
	Paid up equity share capital	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03
	Face value of equity share capital	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001
15	Earnings per share								
	- Basic	0.060	0.099	0.075	0.325	0.060	0.099	0.075	0.325
	- Diluted	0.060	0.099	0.075	0.325	0.060	0.099	0.075	0.325




Notes to the results:

- 1 The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 12.08.2022 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- 2 The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2022.
- 3 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 4 The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs,Biotech Products and Intermediates".Previous period"s figures have been rearranged/regrouped wherever necessary.
- 5 Adjustment of actuarial valuation in respect of compliance with Accounting Standard- IAS-19-'Employee Benefits' is to be done at the year end.
- 6 The quarterly unaudited financial results for the Quarter ended June 30, 2022 are available on the Company's Website i.e;www.gennexlab.com and also available on BSE website i.e; www.bseindia.com.

Place: Hyderabad
Date: 12.08.2022

**For and on behalf of the Board
For Gennex Laboratories Limited**



T.M.Gopalakrishnan
Whole Time Director
DIN # 03137458



Gennex Laboratories Limited

Segment Reporting (Country Wise)


Rs. In Lakhs

The following table Shows the distribution of the Company's revenue based on the location of the customers:

Particulars	Quarterly			Yearly
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
Algeria	1.65	1.63	-	1.63
Argentina	-	-	-	-
Bangladesh	6.15	19.58	2.89	54.63
Bolivia	2.83	-	-	5.36
Colombia	220.28	511.07	39.64	1,404.59
Ecuador	-	-	-	43.16
Egypt	103.89	141.51	177.93	697.91
El Salvador	34.36	7.26	-	7.26
France	3.51	-	-	-
Germany	2.09	26.99	12.44	133.40
Guatemala	50.99	105.01	5.21	169.81
India	827.58	732.44	634.16	2,760.93
Iran	-	60.50	-	60.50
Israel	-	-	-	-
Jordan	-	4.62	-	8.07
Kenya	-	2.05	-	2.05
Mexico	-	-	-	-
Netherlands	-	-	-	3.26
Nicaragua	-	-	-	-
Panama City	-	-	-	2.04
Peru	48.92	110.20	-	222.69
Saudi Arabia	-	-	-	-
Spain	-	44.17	2.01	51.01
Swizerland	-	1.38	-	4.19
Turkey	2.03	0.86	2.62	3.47
Vietnam	89.45	244.48	146.51	467.49
Yeman	-	4.05	13.88	17.93
	1,393.73	2,017.80	1,037.29	6,121.38

For Gennex Laboratories Limited

T M Gopalakrishnan



T M Gopalakrishnan

Whole-time Director

DIN# 03137458

Date: 12.08.2022

Place: Hyderabad

Limited Review Report On Unaudited Standalone Quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors,
Gennex Laboratories Limited

We have reviewed the accompanying statement of unaudited Standalone Financial Results of **GENNEX LABORATORIES LIMITED** (“the Company”) for the Quarter Ended 30th June, 2022 (“the Statement”), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of The Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention , except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are subject to confirmations/reconciliations. The impact of same is unascertainable.

Subject to stated above, our conclusion on the Statement is not modified.

For PPKG & Co.
Chartered Accountants
FRN No.009655S


Giridhari Lal Toshniwal
(Partner)
M.No.205140
UDIN: 22205140 A0XA SF 5812



Place: Hyderabad
Date: 12/08/2022

Limited Review Report On Unaudited Consolidated Quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors,
Gennex Laboratories Limited,
Hyderabad.


1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Gennex Laboratories Limited** ("the Company") and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended 30th June, 2022 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th June, 2022 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of **Deccan Remedies Limited (Associate company)**
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are subject to confirmations/reconciliations. The impact of same is unascertainable. Our Conclusion is not modified in respect of this matter.
7. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs.0.00 lakhs, total net Profit after tax of Rs. 0.00 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended June, 2022 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.
8. Attention is drawn to the fact that the figures for the 3 months ended 31st March, 2022 as reported in this unaudited Consolidated Financial Results are the balancing figures between Audited figures in respect of the full previous Financial Year and the published year to date figures upto the 3rd Quarter of the previous financial year. The figures upto the end of the 3rd Quarter of previous financial year had only been reviewed and not subjected to audit.
9. Subject to Para 6 stated above, our conclusion on the Statement is not modified.

For PPKG & Co.
Chartered Accountants
FRN No: 009655S


Girdhari Lal Toshniwal
(Partner)
M.No:205140



Place: Hyderabad
Date: 12/08/2022

UDIN NO - 22205140A0XAXM5375